NCT03784378View on ClinicalTrials.gov

Continued Access to RXDX-105

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

December 14, 2018

Primary Completion Date

September 30, 2020

Study Completion Date

September 30, 2020

Conditions
Non Small Cell Lung CancerOvarian CancerRET Gene MutationBRAF Gene Mutation
Interventions
DRUG

RXDX-105

RXDX-105 capsules will be administered orally on a continuous daily dosing regimen. Patients will be continue to be treated at the dose level they were previously treated on during participation on Study of RXDX-105.

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center 1275 York Avenue, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT03784378 - Continued Access to RXDX-105 | Biotech Hunter | Biotech Hunter